AR108450A1 - Ésteres de oxaborol y sus usos - Google Patents
Ésteres de oxaborol y sus usosInfo
- Publication number
- AR108450A1 AR108450A1 ARP170101250A ARP170101250A AR108450A1 AR 108450 A1 AR108450 A1 AR 108450A1 AR P170101250 A ARP170101250 A AR P170101250A AR P170101250 A ARP170101250 A AR P170101250A AR 108450 A1 AR108450 A1 AR 108450A1
- Authority
- AR
- Argentina
- Prior art keywords
- membered
- saturated
- nitrogen
- oxygen
- partially unsaturated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde: R¹ es hidrógeno o C₁₋₆ alifático; R¹ᵃ es hidrógeno o C₁₋₆ alifático; o R¹ y R¹ᵃ se toman junto con el átomo de carbono al que están unidos para formar un anillo espiro carbocíclico de 3 a 6 miembros opcionalmente sustituido; cada R² es independientemente hidrógeno, -halógeno, -OR, -NO₂, -CN, -SR, -N(R)₂, -C(O)R, -C(O)OR, -S(O)R, -S(O)₂R, -C(O)N(R)₂, -SO₂N(R)₂, -OC(O)R, -N(R)C(O)R, -N(R)C(O)OR, -N(R)SO₂R, -OC(O)N(R)₂, o un grupo opcionalmente sustituido seleccionado del grupo que consiste en C₁₋₆ alifático y carbociclilo monocíclico saturado o parcialmente insaturado de 3 a 6 miembros; R³ es hidrógeno u C₁₋₆ alifático opcionalmente sustituido; R⁴ es hidrógeno, un grupo de cadena lateral de aminoácido natural o no natural, o un grupo opcionalmente sustituido seleccionado del grupo que consiste en C₁₋₆ alifático, carbociclilo monocíclico saturado o parcialmente insaturado de 3 a 7 miembros, y fenilo; o R³ y R⁴ se toman junto con el átomo de carbono unido a R⁴ y el átomo de nitrógeno unido a R³ para formar un anillo heterociclilo de 3 a 6 miembros opcionalmente sustituido que tiene 0 - 1 heteroátomos adicionales seleccionados de oxígeno, nitrógeno o azufre; R⁵ es hidrógeno o C₁₋₆ alifático opcionalmente sustituido; o R⁴ y R⁵ se toman junto con el átomo de carbono al que están unidos para formar un anillo opcionalmente sustituido seleccionado de un anillo espiro heterocíclico de 3 a 6 miembros que tiene 1 - 2 heteroátomos seleccionados de oxígeno, nitrógeno o azufre y un anillo espiro carbocíclico monocíclico saturado o parcialmente insaturado de 3 a 6 miembros; L es un enlace covalente o una cadena de hidrocarburos, recta o ramificada, C₁₋₁₀ bivalente saturada o insaturada, en donde una, dos o tres unidades de metileno de L son opcionalmente e independientemente reemplazadas por -Cy-, -O-, -SO-, -SO₂-, -C(O)-, -C(O)N(R)-, -S-, -N(R)-, -C(O)O-, -OC(O)-, -N(R)C(O)-, -N(R)SO₂-, o -SO₂N(R)-; en donde cada -Cy- es independientemente un anillo bivalente opcionalmente sustituido seleccionado del grupo consistente en fenileno, carbociclileno monocíclico de 3 a 7 miembros saturado o parcialmente insaturado, heterociclileno monocíclico saturado o parcialmente insaturado de 3 a 7 miembros que tiene 1 - 2 heteroátomos seleccionados de oxígeno, nitrógeno o azufre, heteroarileno de 5 a 6 miembros que tiene 1 - 4 heteroátomos seleccionados de oxígeno, nitrógeno o azufre, carbociclileno bicíclico saturado o parcialmente insaturado de 7 a 10 miembros, arileno bicíclico de 8 a 10 miembros, heterociclileno bicíclico saturado o parcialmente insaturado de 7 a 10 miembros que tiene 1 a 4 heteroátomos seleccionados de oxígeno, nitrógeno o azufre, y heteroarileno bicíclico de 7 a 10 miembros que tiene 1 a 4 heteroátomos seleccionados de oxígeno, nitrógeno o azufre; R⁶ es hidrógeno, -halógeno, -OR, -NO₂, -CN, -SR, -N(R)₂, -C(O)R, -C(O)OR, -S(O)R, -S(O)₂R, -C(O)N(R)₂, -SO₂N(R)₂, -OC(O)R, -N(R)C(O)R, -N(R)C(O)OR, -N(R)SO₂R, -OC(O)N(R)₂, un grupo opcionalmente sustituido seleccionado del grupo consistente en C₁₋₆ alifático, fenilo, carbocíclico monocíclico de 3 a 7 miembros saturado o parcialmente insaturado, heterociclilo monocíclico saturado o parcialmente insaturado de 3 a 7 miembros que tiene 1 - 2 heteroátomos seleccionados de oxígeno, nitrógeno o azufre, heteroarilo de 5 a 6 miembros que tiene 1 - 4 heteroátomos seleccionados de oxígeno, nitrógeno o azufre, carbociclilo bicíclico saturado o parcialmente insaturado de 7 a 10 miembros, arilo bicíclico de 8 a 10 miembros, heterociclilo bicíclico saturado o parcialmente insaturado de 7 a 10 miembros que tiene 1 a 4 heteroátomos seleccionados de oxígeno, nitrógeno o azufre, y heteroarilo bicíclico de 7 a 10 miembros que tiene 1 a 4 heteroátomos seleccionados de oxígeno, nitrógeno o azufre y bicíclico puenteado; cada R es independientemente hidrógeno o C₁₋₆ alifático opcionalmente sustituido; en donde L es un enlace covalente, entonces R⁶ es diferente de -OR, -halógeno, -NO₂, -CN, -SR, -N(R)₂, -S(O)R, -S(O)₂R, -SO₂N(R)₂, -OC(O)R, -N(R)C(O)R, -N(R)C(O)OR, -N(R)SO₂R, o -OC(O)N(R)₂; y en donde L es diferente de un enlace covalente que incluye un átomo de carbono enlazado al oxígeno carboxilo denotado O*.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662335565P | 2016-05-12 | 2016-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108450A1 true AR108450A1 (es) | 2018-08-22 |
Family
ID=58699201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101250A AR108450A1 (es) | 2016-05-12 | 2017-05-11 | Ésteres de oxaborol y sus usos |
| ARP180103435A AR113543A2 (es) | 2016-05-12 | 2018-11-23 | Ésteres de oxaborol y sus usos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103435A AR113543A2 (es) | 2016-05-12 | 2018-11-23 | Ésteres de oxaborol y sus usos |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US10562921B2 (es) |
| EP (2) | EP3455227A1 (es) |
| JP (2) | JP6715957B2 (es) |
| KR (2) | KR102243775B1 (es) |
| CN (2) | CN109503637B (es) |
| AR (2) | AR108450A1 (es) |
| AU (2) | AU2017263785B2 (es) |
| BR (2) | BR122018076188A2 (es) |
| CA (1) | CA3023490C (es) |
| CL (2) | CL2018003187A1 (es) |
| CO (1) | CO2018012077A2 (es) |
| CR (2) | CR20180502A (es) |
| DK (1) | DK3578562T3 (es) |
| EA (2) | EA036661B1 (es) |
| EC (2) | ECSP18091065A (es) |
| ES (1) | ES2882782T3 (es) |
| HK (1) | HK1258717A1 (es) |
| HU (1) | HUE056320T2 (es) |
| IL (2) | IL262453A (es) |
| MA (1) | MA44968A (es) |
| MX (2) | MX2018013743A (es) |
| NI (2) | NI201801171A (es) |
| NZ (1) | NZ746906A (es) |
| PE (2) | PE20191077A1 (es) |
| PT (1) | PT3578562T (es) |
| SG (1) | SG11201809237RA (es) |
| TN (2) | TN2018000351A1 (es) |
| TW (1) | TWI629279B (es) |
| UA (2) | UA120999C2 (es) |
| UY (2) | UY37236A (es) |
| WO (1) | WO2017195069A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11039617B2 (en) | 2013-01-30 | 2021-06-22 | Agrofresh Inc. | Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness |
| US10070649B2 (en) | 2013-01-30 | 2018-09-11 | Agrofresh Inc. | Volatile applications against pathogens |
| WO2017155879A1 (en) | 2016-03-07 | 2017-09-14 | Agrofresh Inc. | Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops |
| KR102243775B1 (ko) * | 2016-05-12 | 2021-04-22 | 아나코르 파마슈티칼스 인코포레이티드 | 옥사보롤 에스터 및 이의 용도 |
| MX2020005464A (es) | 2017-11-30 | 2020-12-03 | Boragen Inc | Compuestos de benzoxaborol y formulaciones de los mismos. |
| JP2020180170A (ja) * | 2019-04-23 | 2020-11-05 | 東ソー株式会社 | ハロゲン含有ポリエーテルポリオール組成物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| GB9411587D0 (en) | 1994-06-09 | 1994-08-03 | Zeneca Ltd | Compound, composition and use |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| JO3396B1 (ar) | 2007-06-20 | 2019-10-20 | Anacor Pharmaceuticals Inc | جزيئات صغيرة تحتوي على البورون |
| WO2010045503A1 (en) * | 2008-10-15 | 2010-04-22 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agents |
| WO2010045505A1 (en) | 2008-10-15 | 2010-04-22 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules as anti-protozoal agents |
| WO2011019618A1 (en) | 2009-08-14 | 2011-02-17 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
| ES2582471T3 (es) | 2011-02-07 | 2016-09-13 | Rempex Pharmaceuticals, Inc. | Inhibidores polibásicos de la bomba de flujo de salida bacteriana que contienen boro y usos terapéuticos de los mismos |
| BR112014008186A2 (pt) | 2011-10-07 | 2017-04-11 | Syngenta Participations Ag | método para proteção de plantas úteis ou material de propagação de plantas |
| AR088669A1 (es) | 2011-11-21 | 2014-06-25 | Lilly Co Eli | Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos |
| US8669207B1 (en) * | 2013-01-30 | 2014-03-11 | Dow Agrosciences, Llc. | Compounds and compositions |
| WO2015013318A1 (en) | 2013-07-22 | 2015-01-29 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| CN105492388B (zh) | 2013-08-09 | 2018-12-21 | 葛兰素史克知识产权第二有限公司 | 三环苯并氧杂硼杂环戊烯化合物及其用途 |
| EP3086645A1 (en) | 2013-12-23 | 2016-11-02 | Syngenta Participations AG | Benzoxaborole fungicides |
| US20180244699A1 (en) * | 2015-08-17 | 2018-08-30 | Syngenta Participations Ag | 1-hydroxy-3h-2,1-benzoxaborole derivatives and their use as microbiocides |
| KR102243775B1 (ko) * | 2016-05-12 | 2021-04-22 | 아나코르 파마슈티칼스 인코포레이티드 | 옥사보롤 에스터 및 이의 용도 |
-
2017
- 2017-05-01 KR KR1020187035848A patent/KR102243775B1/ko active IP Right Grant
- 2017-05-01 CA CA3023490A patent/CA3023490C/en active Active
- 2017-05-01 SG SG11201809237RA patent/SG11201809237RA/en unknown
- 2017-05-01 EA EA201892475A patent/EA036661B1/ru not_active IP Right Cessation
- 2017-05-01 WO PCT/IB2017/052522 patent/WO2017195069A1/en active Application Filing
- 2017-05-01 EP EP17722886.3A patent/EP3455227A1/en not_active Withdrawn
- 2017-05-01 BR BR122018076188A patent/BR122018076188A2/pt not_active Application Discontinuation
- 2017-05-01 ES ES19180969T patent/ES2882782T3/es active Active
- 2017-05-01 CN CN201811522724.7A patent/CN109503637B/zh active Active
- 2017-05-01 UA UAA201810456A patent/UA120999C2/uk unknown
- 2017-05-01 PT PT191809698T patent/PT3578562T/pt unknown
- 2017-05-01 JP JP2018559924A patent/JP6715957B2/ja not_active Expired - Fee Related
- 2017-05-01 PE PE2019000887A patent/PE20191077A1/es unknown
- 2017-05-01 NZ NZ746906A patent/NZ746906A/en not_active IP Right Cessation
- 2017-05-01 CN CN201780029103.2A patent/CN109153688A/zh active Pending
- 2017-05-01 MA MA044968A patent/MA44968A/fr unknown
- 2017-05-01 KR KR1020187035855A patent/KR102231489B1/ko active IP Right Grant
- 2017-05-01 MX MX2018013743A patent/MX2018013743A/es unknown
- 2017-05-01 BR BR122023022427-2A patent/BR122023022427A2/pt unknown
- 2017-05-01 AU AU2017263785A patent/AU2017263785B2/en not_active Ceased
- 2017-05-01 CR CR20180502A patent/CR20180502A/es unknown
- 2017-05-01 TN TNP/2018/000351A patent/TN2018000351A1/en unknown
- 2017-05-01 CR CR20180560A patent/CR20180560A/es unknown
- 2017-05-01 EP EP19180969.8A patent/EP3578562B1/en active Active
- 2017-05-01 UA UAA201811418A patent/UA121354C2/uk unknown
- 2017-05-01 EA EA201892203A patent/EA034415B1/ru unknown
- 2017-05-01 TN TNP/2019/000106A patent/TN2019000106A1/en unknown
- 2017-05-01 HU HUE19180969A patent/HUE056320T2/hu unknown
- 2017-05-01 PE PE2018002055A patent/PE20190119A1/es unknown
- 2017-05-01 DK DK19180969.8T patent/DK3578562T3/da active
- 2017-05-09 TW TW106115364A patent/TWI629279B/zh not_active IP Right Cessation
- 2017-05-09 US US15/590,159 patent/US10562921B2/en active Active
- 2017-05-10 UY UY0001037236A patent/UY37236A/es unknown
- 2017-05-11 AR ARP170101250A patent/AR108450A1/es unknown
-
2018
- 2018-10-17 IL IL262453A patent/IL262453A/en unknown
- 2018-11-08 CO CONC2018/0012077A patent/CO2018012077A2/es unknown
- 2018-11-09 MX MX2018015410A patent/MX2018015410A/es unknown
- 2018-11-09 NI NI2018001171A patent/NI201801171A/es unknown
- 2018-11-09 CL CL2018003187A patent/CL2018003187A1/es unknown
- 2018-11-09 NI NI2018001172A patent/NI201801172A/es unknown
- 2018-11-16 AU AU2018264116A patent/AU2018264116B2/en not_active Ceased
- 2018-11-20 IL IL263161A patent/IL263161B/en unknown
- 2018-11-22 UY UY0001037980A patent/UY37980A/es unknown
- 2018-11-23 AR ARP180103435A patent/AR113543A2/es unknown
- 2018-11-27 CL CL2018003377A patent/CL2018003377A1/es unknown
- 2018-12-11 EC ECSENADI201891065A patent/ECSP18091065A/es unknown
-
2019
- 2019-01-22 HK HK19101118.4A patent/HK1258717A1/zh unknown
- 2019-01-24 JP JP2019009932A patent/JP6715966B2/ja not_active Expired - Fee Related
- 2019-04-12 EC ECSENADI201926702A patent/ECSP19026702A/es unknown
- 2019-09-24 US US16/580,676 patent/US10882872B2/en active Active
-
2020
- 2020-12-01 US US17/108,066 patent/US11578087B2/en active Active
-
2022
- 2022-12-22 US US18/145,315 patent/US20230132298A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108450A1 (es) | Ésteres de oxaborol y sus usos | |
| AR103138A1 (es) | Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| CY1123548T1 (el) | Παραγωγα ινδολιου για χρηση στην ιατρικη | |
| AR096242A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR096241A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR106798A1 (es) | Inhibidores pirazol de acc y usos de los mismos | |
| AR124483A2 (es) | Compuestos heterocíclicos útiles como inhibidores de pdk1 | |
| AR114164A1 (es) | Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| AR106806A1 (es) | Inhibidores triazol de acc y usos de los mismos | |
| AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR067354A1 (es) | Compuestos utiles como inhibidores de la raf quinasa | |
| AR114828A1 (es) | Compuestos de pteridinona y sus usos | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR101395A1 (es) | Derivados de indolizina y su uso en enfermedades neurodegenerativas | |
| AR105893A1 (es) | Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato | |
| AR091273A1 (es) | Inhibidores de pirimidinil tirosina quinasa | |
| AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) | |
| MX2020004902A (es) | Derivados del acido oxoacridinilo acetico y metodos de uso. | |
| AR119010A1 (es) | Compuestos, composiciones y métodos de uso | |
| AR117472A1 (es) | Inhibidores de tienopiridina de ripk2 | |
| AR101290A1 (es) | Inhibidores de aldosterona sintasa | |
| AR097795A1 (es) | Derivados de n-arilmetilo sulfonamida como moduladores negativos de nr2a | |
| AR110238A1 (es) | Derivado de pirido[3,4-d]pirimidina y su sal farmacéuticamente aceptable |